Adherence and drug resistance: predictions for therapy outcome
about
Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation modelsOptimal timing and duration of induction therapy for HIV-1 infectionRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionEarly HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM PopulationsModelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: a mathematical approachModelling imperfect adherence to HIV induction therapyA Bayesian Approach in Differential Equation Dynamic Models Incorporating Clinical Factors and Covariates.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials.Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach.HIV therapy: managing resistance.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibilityExploring ART intake scenes in a human rights-based intervention to improve adherence: a randomized controlled trialMeasuring health-related stigma--a literature review.Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.Modeling HIV persistence, the latent reservoir, and viral blips.Threshold virus dynamics with impulsive antiretroviral drug effectsEconomic impact of poor compliance with pharmaceuticals.Maximum equilibrium prevalence of mosquito-borne microparasite infections in humans.Barriers and facilitators to patients' adherence to antiretroviral treatment in Zambia: a qualitative study.A comparative analysis of the relative efficacy of vector-control strategies against dengue fever.Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.The expected and unexpected benefits of dispensing the exact number of pills.Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.The role of family caregivers in HIV medication adherence.Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule.Life cycle synchronization is a viral drug resistance mechanism.Dynamics of recurrent viral infection.Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?Immune responses and the emergence of drug-resistant virus strains in vivo.Insight into treatment of HIV infection from viral dynamics models
P2860
Q27015861-8BCBA708-2328-4A1B-970F-E43A5B0B4B3DQ28469250-6910EA07-9347-4056-8421-491ABFE47E5BQ28545971-2FA63928-2F69-4981-B47B-93095CEE00F7Q28550445-09DAC73D-1646-48C4-B5D4-D4D5E2C3DF07Q30685690-B9FCDB67-AFC8-4DBA-AF39-32F5CAAF7A49Q30892194-9E6EAD89-A60D-4829-9E60-7AC1ED1728EBQ33516173-22A86891-4409-40E3-BDA6-BD759D60A67EQ33523201-9830BD7D-DCDD-4419-A7CE-EE0D44C6CD5BQ33824478-1531D841-65AA-44D9-B9BC-563C1FF5385CQ34573789-B0D5B074-CC27-4ABB-A427-4B7B78AA1A73Q34822693-DB9D67A1-FFCC-4065-B171-2093E59E10ECQ35422530-57767F1C-ECE7-4B5B-B914-34C24100FDB0Q36104156-D7E5F9A0-30ED-4020-A98F-E43AD960E4BFQ36374300-179823F2-D8AD-4052-B0B5-67A0853FA3F3Q36492224-11F76FEC-1625-4766-8E92-1368A02421A0Q36542552-50761EB8-47A8-49EF-B34F-27E7E4BA9E31Q36665809-25D62E19-9A45-45F6-A74C-23F92D9EBF5BQ36675928-C1FDFE16-B6D8-4C45-9E8E-BE68BC323D09Q37365718-02270F8D-FCBB-4286-8A10-B61A679214CBQ37458961-BEC32E95-6510-4430-8F62-C73A481EE546Q37609268-EE2F50A1-D6B0-4F7F-9378-0E9A1E6DA615Q38871901-0DF7AA94-7AEF-421E-832D-B1C405A01149Q39428773-3A098CD0-B686-4BE0-80C8-950C4E55AC74Q40214733-D8BBB838-D6C6-4E85-8B84-84CD47F4DD22Q40246920-656FDDFF-6F1D-4FDB-A9B9-FC03981D7326Q41677512-3EA0FAAB-BEAE-47BF-901B-CDA53F37784EQ41760696-6E5B1255-821C-4311-BF95-8F746C953A1FQ42690963-A1BC1840-EAC2-4C19-A88F-53D188FD34F9Q43260037-8382D530-AEB0-4E24-BF14-C91CC2EC305AQ45090413-85166A8A-2545-4ED9-BE5C-07D046803CE3Q45351952-0E15A6D0-3EDE-42BD-8740-DA9A702447A3Q49980878-ACD9DF62-830B-4972-90FC-17BF9BABCDEBQ51935630-C879E3E8-33B5-40E2-B598-E7E610D78FE9Q51946107-359411B9-D50B-4D25-B995-C4D4FBB53E36Q51992080-C3CDBF3D-6801-4F70-A574-A01A6036AD9CQ58788145-3A59E172-6790-460B-87C7-F91CD32B6FB8
P2860
Adherence and drug resistance: predictions for therapy outcome
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Adherence and drug resistance: predictions for therapy outcome
@ast
Adherence and drug resistance: predictions for therapy outcome
@en
Adherence and drug resistance: predictions for therapy outcome
@nl
type
label
Adherence and drug resistance: predictions for therapy outcome
@ast
Adherence and drug resistance: predictions for therapy outcome
@en
Adherence and drug resistance: predictions for therapy outcome
@nl
prefLabel
Adherence and drug resistance: predictions for therapy outcome
@ast
Adherence and drug resistance: predictions for therapy outcome
@en
Adherence and drug resistance: predictions for therapy outcome
@nl
P2860
P356
P1476
Adherence and drug resistance: predictions for therapy outcome
@en
P2093
P2860
P304
P356
10.1098/RSPB.2000.1079
P577
2000-04-22T00:00:00Z